A global survey on the use of the international classification of diseases codes for metabolic dysfunction‑associated fatty liver disease
dc.authorid | 0000-0002-8909-2102 | |
dc.contributor.author | Zhang, Huai | |
dc.contributor.author | Targher, Giovanni | |
dc.contributor.author | Byrne, Christopher D. | |
dc.contributor.author | Kim, Seung Up | |
dc.contributor.author | Wong, Vincent Wai-Sun | |
dc.contributor.author | Valenti, Luca | |
dc.contributor.author | Glickman, Myer | |
dc.contributor.author | Ponce, Jaime | |
dc.contributor.author | Mantzoros, Christos S. | |
dc.contributor.author | Örmeci, Necati | |
dc.contributor.author | Zou, Zhuo-Lin | |
dc.date.accessioned | 2024-09-24T07:00:00Z | |
dc.date.available | 2024-09-24T07:00:00Z | |
dc.date.issued | 2024 | |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | |
dc.description.abstract | Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision. | |
dc.identifier.citation | Zhang, H., Targher, G., Byrne, C.D. et al. (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International, 18(4), 1178–1201. https://doi.org/10.1007/s12072-024-10702-5 | |
dc.identifier.doi | 10.1007/s12072-024-10702-5 | |
dc.identifier.endpage | 1201 | |
dc.identifier.issn | 1936-0541 | |
dc.identifier.issn | 1936-0533 | |
dc.identifier.issue | 4 | |
dc.identifier.pmid | PMID: 38878111 | |
dc.identifier.scopus | 2-s2.0-85196002868 | |
dc.identifier.scopusquality | Q1 | |
dc.identifier.startpage | 1178 | |
dc.identifier.uri | https://doi.org/10.1007/s12072-024-10702-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.13055/798 | |
dc.identifier.volume | 18 | |
dc.identifier.wos | WOS:001252919400001 | |
dc.identifier.wosquality | Q1 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.indekslendigikaynak.other | SCI-E - Science Citation Index Expanded | |
dc.institutionauthor | Örmeci, Necati | |
dc.institutionauthorid | 0000-0002-8909-2102 | |
dc.language.iso | en | |
dc.relation.ispartof | Hepatology International | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Global survey | |
dc.subject | ICD-11 | |
dc.subject | MAFLD | |
dc.title | A global survey on the use of the international classification of diseases codes for metabolic dysfunction‑associated fatty liver disease | |
dc.type | Article | |
dspace.entity.type | Publication |